Bull&Bear | Monte Rosa and Porch Group Lead the Charge in Market Gains

Top Gainers:

Monte Rosa (GLUE) surged by 93.87%, marking a three-day gain of 94.66%. Monte Rosa Therapeutics has entered a global licensing agreement with a major pharmaceutical company to advance Vav1-directed molecular glue degraders that regulate T and B cells.

Porch Group (PRCH) increased by 70.31%. Porch Group announced the approval from the Texas Department of Insurance to establish and license Porch Insurance Mutual Exchange, a new homeowner's insurance mutual. This approval is considered a significant milestone.

Sangamo Therapeutics (SGMO) rose by 36.00%, continuing a two-day increase of 36.91%. Shareholders have confidence in the loss-making Sangamo Therapeutics, as the stock price rose by 55% over the past week, achieving a one-year gain of 221%.

PROCEPT BioRobotics (PRCT) climbed 32.33%, with a two-day gain of 36.17%. Procept BioRobotics anticipates 2024 revenue to be between $222.5 million and $223 million, previously forecasted at $217 million, with consensus at $217.64 million.

Triller Group (ILLR) advanced by 30.87%, continuing a two-day rise of 30.87%. Triller Group has appointed Kevin McGurn as CEO.

Top Losers:

Dogness (DOGZ) dropped by 17.63%, continuing a two-day decline of 17.72%. The 42% spike in Dogness's stock appears illogical, potentially impacted by overall market weakness and rising treasury yields, leading to a general downturn in sector shares.

Philips (PHG) fell by 15.95%, with a two-day decrease of 17.30%. Philips's third-quarter sales unexpectedly declined, prompting the company to lower its full-year sales forecast.

Alarum Technologies (ALAR) decreased by 12.84%. Alarum Technologies had its price target lowered by a financial institution to $28 from $42. Although the buy rating was maintained, the reduced target negatively impacted the stock price.

Ritter Logistics Technology (RITR) declined by 10.90%. Ritter Logistics Technology released a 6-K foreign issuer report indicating uncertainties in company performance.

Nuvectis Pharma (NVCT) dropped by 10.50%. Nuvectis Pharma announced a presentation on NXP900 at the 2024 AACR International Conference on Molecular Targets and Cancer Therapeutics.